Nur Nicholson - Apellis Pharmaceuticals Chief Officer

All Insiders . USA . 
Stock . Apellis Pharmaceuticals . Stakeholders . Insider . Nur Nicholson
APLS Stock  USD 30.77  3.02  10.88%   

Insider

Nur Nicholson is Chief Officer of Apellis Pharmaceuticals
Age 54
Address 100 Fifth Avenue, Waltham, MA, United States, 02451
Phone617 977 5700
Webhttps://www.apellis.com

Latest Insider Transactions

2024-03-13Disposed of 11220 shares @ 57.56View

Nur Nicholson Latest Insider Activity

Tracking and analyzing the buying and selling activities of Nur Nicholson against Apellis Pharmaceuticals stock is an integral part of due diligence when investing in Apellis Pharmaceuticals. Nur Nicholson insider activity provides valuable insight into whether Apellis Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Apellis Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Apellis Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Nur Nicholson over six months ago
Disposition of 3452 shares by Nur Nicholson of Apellis Pharmaceuticals at 58.1335 subject to Rule 16b-3

Apellis Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0656) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.
Apellis Pharmaceuticals currently holds 110.93 M in liabilities with Debt to Equity (D/E) ratio of 0.63, which is about average as compared to similar companies. Apellis Pharmaceuticals has a current ratio of 7.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Apellis Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Susan MSEliem Therapeutics
N/A
BBA CPALumos Pharma
57
David MBASeres Therapeutics
63
Jeff NelsonMilestone Pharmaceuticals
43
Kimberly SheehanMilestone Pharmaceuticals
N/A
Kristin AinsworthSeres Therapeutics
N/A
Peter RhodeHCW Biologics
66
Bradley JDLumos Pharma
45
James JDEliem Therapeutics
58
Carl LangrenLumos Pharma
69
MD BALumos Pharma
69
Jo PalmerPhillipsEliem Therapeutics
N/A
Guy RousseauMilestone Pharmaceuticals
N/A
Richard HawkinsLumos Pharma
75
Robert MBAEliem Therapeutics
56
FACC FAHAMilestone Pharmaceuticals
66
Hing WongHCW Biologics
70
Erin LavelleEliem Therapeutics
47
Lorenz MullerMilestone Pharmaceuticals
60
Lisa MillerLumos Pharma
N/A
Philippe MBAMilestone Pharmaceuticals
62
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. Apellis Pharmaceuticals (APLS) is traded on NASDAQ Exchange in USA. It is located in 100 Fifth Avenue, Waltham, MA, United States, 02451 and employs 702 people. Apellis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-1.07
Return On Asset-0.16

Apellis Pharmaceuticals Leadership Team

Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Timothy Sullivan, CFO, Treasurer
Cedric MD, President, CoFounder
Meredith Kaya, Investor President
Adam Townsend, Chief Commercial Officer
James CPA, Corporate VP
Karen Lewis, Chief Officer
Nur Nicholson, Chief Officer
JD Esq, General Counsel
MBA JD, CoFounder Director
Pr MD, Head Board
David Acheson, Senior Commercial
Lukas MD, Chief Officer
Mark Delong, Chief Officer
Federico MD, CoFounder Officer
Victoria Brown, Senior President
Pascal Deschatelets, CoFounder Officer
Caroline MD, Chief Officer
Jeffrey Eisele, Chief Officer

Apellis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.07
Return On Asset-0.16
Profit Margin(0.35) %
Operating Margin(0.24) %
Current Valuation3.9 B
Shares Outstanding124.39 M
Shares Owned By Insiders13.98 %
Shares Owned By Institutions97.46 %
Number Of Shares Shorted20.79 M
Price To Earning(6.94) X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY